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ABSTRACT
Objective: The objective of this study was to identify the
most cost-effective statin or combination of statins, from
the perspective of a managed care payer.
Methods: A  decision-analytic  model  compared  the
cost-effectiveness of titration to goal with atorvastatin,
ﬂuvastatin, lovastatin, pravastatin, rosuvastatin, and sim-
vastatin in patients with elevated low-density lipoprotein
cholesterol (LDL-C). Effectiveness measures included the
percentage change from baseline LDL-C and high-density
lipoprotein cholesterol (HDL-C), and the percentage of
patients achieving National Cholesterol Education Pro-
gram (NCEP) Second Adult Treatment Panel (ATP II)
LDL-C goals. Direct medical costs were calculated based
on drug, physician, and laboratory resource use, multi-
plied by wholesale acquisition costs for drugs and the
2005 Medicare reimbursement rates for services. A
Monte Carlo simulation tested the sensitivity of results to
model efﬁcacy inputs.
Results: In the base-case analysis, rosuvastatin domi-
nated atorvastatin, pravastatin, and simvastatin. Generic
lovastatin dominated ﬂuvastatin. The incremental
(absolute) reduction in LDL-C, increase in HDL-C, and
increase in patients to goal with rosuvastatin compared
with lovastatin were 16%, 3%, and 27%, respectively.
Incremental costs per additional 1% reduction in LDL-C,
1% increase in HDL-C, and patient to goal with rosuv-
astatin versus lovastatin were $8, $41, and $436, respec-
tively. A wide variety of assumptions were assessed and
Monte Carlo sensitivity analyses were conducted. Find-
ings were most sensitive to the cost of lovastatin.
Conclusion: Rosuvastatin dominates atorvastatin, prav-
astatin, and simvastatin because it is more effective and
less costly, and it may be considered cost-effective
compared with generic lovastatin. The most cost-effective
two-statin formulary contained lovastatin and
rosuvastatin.
Keywords: cost-effectiveness, hydroxymethylglutaryl-
CoA reductase inhibitors, hypercholesterolemia, man-
aged care.
Background
Cardiovascular disease (CVD) accounts for more
than 930,000 deaths annually in the United States,
including more than 500,000 deaths from coronary
heart disease (CHD) [1]. The annual cost of CVD is
$368 billion, including $227 billion in direct medi-
cal expenditures [1]. Since 1994, numerous large
clinical trials have shown that 3-hydroxy-3-methyl-
glutaryl-coenzyme A reductase inhibitors (statins)
signiﬁcantly reduce the incidence of cardiovascular
morbidity and mortality [2–8].
Although the rate of statin use has risen in recent
years [9,10], there is substantial unmet need for
lipid-lowering in the US population. Rates of cho-
lesterol testing and use of lipid-lowering medica-
tions remain low, particularly among high-risk
patients [11–13]. Among those who are treated,
low-density lipoprotein cholesterol (LDL-C) goals
are achieved in fewer than half of patients [14], even
after statin therapy is titrated [15]. The 1999–2000
National Health and Nutrition Examination Survey
(NHANES) revealed that awareness, treatment, and
control of hypercholesterolemia among US adults
have changed little in the past decade [16].
Clinical and economic considerations in the man-
agement of dyslipidemia have changed substantially
since the most recent NHANES data were collected.
The availability of generic lovastatin has substan-
tially lowered the cost to initiate therapy within this
class. Ezetimibe, a cholesterol absorption inhibitor,
is a new adjunct to statin therapy in patients who
fail to achieve goals on monotherapy. Finally, rosu-
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vastatin became the sixth statin available in the
United States after its approval by the Food and
Drug Administration in July 2003. Long-term out-
comes data are not yet available for rosuvastatin,
but in a 6-week comparative clinical trial, rosuvas-
tatin 10 mg to 40 mg lowered LDL-C to levels
<100 mg/dL in a signiﬁcantly higher proportion of
patients compared with groups receiving equivalent
doses of atorvastatin or equivalent and higher doses
of simvastatin and pravastatin [17].
The general aim of this study was to assist man-
aged care decision-makers as they reevaluate statin
formularies in light of these new therapeutic alter-
natives. The speciﬁc objective was to identify the
most cost-effective statin(s) from a payer perspec-
tive, based on the currently available clinical data
and guidelines.
Methods
A cost-effectiveness analysis (CEA) was designed to
inform statin selection in a managed care setting. A
decision-analytic model was constructed that com-
pared the treatment costs and effectiveness of each
statin. Consistent with the Academy of Managed
Care Pharmacy (AMCP) Format for Formulary
Submissions Version 2.0 [18], the analysis em-
ployed the payer perspective, hence only direct
medical costs, and time horizons of one and 3 years
(a lifetime analysis was not conducted because long-
term clinical data were not yet available for all of
the treatments used in the model). The statins and
their starting and maximum dosages included ator-
vastatin 10 mg to 80 mg, ﬂuvastatin 40 mg to
80 mg, generic lovastatin 20 mg to 40 mg, pravas-
tatin 20 mg to 40 mg, rosuvastatin 10 mg to 40 mg,
and simvastatin 20 mg to 80 mg. Doses were
titrated to target LDL-C levels speciﬁed in the Sec-
ond Adult Treatment Panel (ATP II) of the National
Cholesterol Education Program (NCEP) or to the
maximum dosage speciﬁed above. Patient-level
effectiveness parameters, derived from clinical trial
data and the published literature, included percent-
age reduction in LDL-C, percentage increase in
high-density lipoprotein cholesterol (HDL-C), and
achievement of ATP II goal. Resource-use parame-
ters were based on treatment guidelines issued by
the Third NCEP Adult Treatment Panel (ATP III)
and included statin costs, physician visits, and lab-
oratory tests. Unit costs were based on Medicare
reimbursement rates and the wholesale acquisition
cost (WAC) of statins. All key parameters were sub-
jected to extensive sensitivity analyses, including
Monte Carlo simulation. Details regarding each of
these elements of the analysis are given below. The
conceptual framework of the model is depicted in
Figure 1. The model was constructed using Excel
2002 (Microsoft Corp.) and @Risk 4.5 (Palisade
Corp.).
The base-case analysis compared the cost-effec-
tiveness of titration to LDL-C goal with each statin
in patients with baseline LDL-C ≥ 160 mg/dL and
<250 mg/dL. To facilitate comparisons between
statins, the incremental cost-effectiveness ratio
(ICER) for each drug was the difference in cost
between the drug and the next less costly alternative
divided by the difference in effectiveness between
the drug and the next less costly alternative [19].
Interventions which are more effective and less
costly than the alternative (dominant) [19] or which
have a lower ICER than the alternative (extended
dominance) are preferred [20]. The undominated
products comprise the “efﬁcient frontier” [19],
which is also referred to in this article as the optimal
statin formulary.
Patient Population
The analysis employed patient-level data from two
multicenter, Phase III, randomized clinical trials.
One compared rosuvastatin with atorvastatin [21]
and the other compared rosuvastatin with pravas-
tatin and simvastatin [22], both over 52 weeks.
These trials had virtually identical inclusion criteria
and protocols, and are the only two long-term trials
Figure 1 Model ﬂow—base case. All patients initiated statin therapy on the recommended starting dose and were titrated at their physicians’
discretion until they achieved their ATP II goal or until they reached the highest available dose. Patients who achieved goal continued on main-
tenance therapy at the current dose. Patients who failed to achieve goal continued on maintenance therapy at the highest available dose.
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that compare rosuvastatin to other statins. In the
Olsson  study  [21],  412  patients  from  45  centers
in northern Europe with LDL-C 160 mg/dL to
249 mg/dL were randomized to rosuvastatin 5 mg,
rosuvastatin 10 mg, or atorvastatin 10 mg. After
12 weeks of treatment, dosages could be sequen-
tially doubled up to 80 mg if the patient was not at
his/her ATP II LDL-C goal. In the Brown study [22],
477 patients from 43 centers in the United States
who met identical inclusion criteria were rand-
omized to rosuvastatin 5 mg, rosuvastatin 10 mg,
pravastatin 20 mg, or simvastatin 20 mg. After
12 weeks of ﬁxed-dose therapy, dosages were
sequentially doubled to a maximum of 80 mg for
rosuvastatin and simvastatin and 40 mg for pravas-
tatin according to investigator discretion if the
patient did not meet his/her ATP II LDL-C goal.
The 52-week observed data from the Olsson [21]
and Brown [22] trials were pooled. Because rosuv-
astatin was substantially more effective in the Euro-
pean (Olsson [21]) study than in the US (Brown
[22]) study, a multivariate linear regression model
was ﬁt to the pooled database of rosuvastatin
patients from both trials. The main effect for the
trial variable (adjusting for clinical and demo-
graphic characteristics that were associated with
effectiveness) was used to weight the 52-week lipid
levels among all Olsson [21] subjects downward to
make them similar to those of Brown [22] subjects.
The range of effectiveness used in sensitivity analy-
sis was broad enough to cover potential error in the
adjustment weights.
Subjects who did not complete the 52-week fol-
low-up period were excluded for three reasons.
First, the objective of this analysis was to estimate
effectiveness and costs in patients treated for at least
1 year. Second, discontinuation rates were low
(<20%) and similar across treatment arms, so drop-
ping these patients could be done without biasing
the results for any particular drug [21,22]. Third,
exclusion of these subjects avoided potentially inac-
curate imputation of costs and effectiveness in the
base-case analysis. In sensitivity analyses, missing
data were imputed for the full intent-to-treat pop-
ulation. Because 10 mg is the recommended starting
dose for rosuvastatin [2], and 75% of all rosuvas-
tatin sold is in the form of 10 mg tablets [24],
patients randomized to 5 mg were also excluded
from this analysis. Based on the characteristics of
included trial participants (atorvastatin n = 116;
pravastatin n = 95; rosuvastatin n = 202; simvasta-
tin n = 102), the hypothetical cohort in the model
was 40% male and had a mean age of 58 years and
a mean baseline LDL of 189 mg/dL. Approximately
23% of the patients were considered “high risk” by
ATP II criteria; another 35% were at moderately
high risk.
Statin Effectiveness
Effectiveness measures included the percentage
change in LDL-C, the percentage change in HDL-C,
and the percentage of patients achieving ATP II
LDL-C goal (Table 1). ATP II goals were used for
this analysis because comparative 1-year effective-
ness data for rosuvastatin is at present only availa-
ble from trials in which subjects were titrated to
ATP II targets. For the base-case analysis, effective-
ness of atorvastatin, pravastatin, rosuvastatin and
simvastatin was based on measurements at 52
weeks (after titration to goal) in the pooled trial
cohort described above. The modest incremental
effectiveness in the “base-case” versus “no titra-
tion” scenarios may have been because titrations
were done after randomization at the physician’s
discretion, so patients who were titrated may have
been farther from goal or treatment-resistant. Five
patients in the trials were titrated to rosuvastatin
80 mg; however, after completion of the clinical
program, a decision was made by the manufacturer
not to pursue marketing approval of the 80 mg
dose. Accordingly, these patients’ 52-week efﬁcacy
data were adjusted by carrying forward their last
observations at the 40 mg dose. Sensitivity analyses
were conducted in which lower and upper 95%
conﬁdence limits were used instead of means for
effectiveness parameters. These ranges were gener-
ally consistent with the results of other long-term
clinical trials [2–5,7,25] and product labels.
Although ﬂuvastatin and lovastatin were not
used in the Olsson [21] and Brown [22] trials, these
low-cost statins were included in the CEA to make
it more relevant to managed care decision-makers.
Effectiveness of these drugs was estimated based on
the principle of dose equivalence. Previous research
suggests that ﬂuvastatin is half as potent as pravas-
tatin, but the two drugs achieve comparable
changes in LDL-C and HDL-C over 52 weeks when
given in equipotent doses [26,27]. Thus, because
pravastatin was given over the 20 mg to 40 mg dose
range in the Brown trial [22], it was assumed that
the results would be comparable to ﬂuvastatin over
the 40 mg to 80 mg dose range. Similarly, lovastatin
20 mg to 40 mg is approximately equivalent to
pravastatin 20 mg to 40 mg [26]. The assumption
that ﬂuvastatin 40 mg to 80 mg and lovastatin
20 mg to 40 mg were equivalent to pravastatin
20 mg to 40 mg in terms of LDL-C reduction,
HDL-C improvement, and ATP II goal achievement
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is also consistent with data from long-term trials of
those drugs [6,8,25].
Costs
Consistent with the managed care perspective,
direct  medical  costs  of  lipid-lowering  therapy
were included in this analysis. First-year total cost
of treatment was estimated based on statin use,
physician ofﬁce visits, and laboratory monitoring
(Table 2). In the base-case analysis, it was assumed
that physician visits and lab tests were performed
according to ATP III guidelines [28]. The model
cohort therefore incurred two physician visits, two
lipid panels, one liver function test (LFT), and one
creatine kinase (CK) test before initiating therapy,
and follow-up visits for titration every 8 weeks until
the maximum dose or LDL-C goal was reached.
Thereafter, follow-up intervals were reduced to
every 6 months. Lipid tests were assumed to occur
at each physician visit, and repeat LFT and CK
assessments were done at week 8 only. The number
of physician visits and lipid tests within the ﬁrst year
of therapy was therefore determined by the number
of titrations required to achieve LDL-C goal.
Average 2005 Medicare reimbursement rates
were used as a measure of the costs of physician vis-
its and laboratory procedures [29,30]. A range of
ﬁve Common Procedural Terminology, Fourth Edi-
tion (CPT-4) codes (99211–99215) for physician
ofﬁce visits were used to estimate this cost. The sec-
ond highest visit level (second most complicated
case) was selected for the base case [31], and the
minimum and maximum values in the range were
used in sensitivity analyses. CPT-4 codes 80061,
80076, and 82550 were chosen to represent the
costs of lipid panels, LFT, and CK, respectively. The
minimum and maximum observed values in the
range were used in the sensitivity analyses for each
parameter.
The WAC (80% of average wholesale price
[AWP]) for the largest-selling package size as of Jan-
uary 19, 2005 was used to determine the daily cost
of each statin. The exception was lovastatin, a mul-
tisource generic product, where the average WAC
across all manufacturers was used [32]. Because
there  is  great  variability  in  net  acquisition  cost
due to unpublished contractual arrangements and
rebates, sensitivity analyses probed a range of WAC
less 25% to WAC plus 25% (equivalent to AWP).
Threshold analyses identiﬁed the percent change in
acquisition cost for each product that was required
to alter the base-case efﬁcient frontier.
Table 1 Statin effectiveness parameters under base-case and alternative scenarios
Statin % Reduction in LDL-C % Increase in HDL-C % Achieving ATP II goal
Atorvastatin 10–80 mg
Base-case (95% CI) 38 (36, 40) 0.9 (−1.3, 3.0) 80 (73, 87)
No titration 36 8.5 70
With ezetimibe 42 9.5 94
Reduced compliance 30 — 52
Fluvastatin 40–80 mg
Base-case (95% CI) 30 (28, 33) 4.4 (2.1, 6.6) 60 (50, 70)
No titration 28 8.3 56
With ezetimibe 36 9.8 86
Reduced compliance 24 — 46
Lovastatin 20–40 mg
Base-case (95% CI) 30 (28, 33) 4.4 (2.1, 6.6) 60 (50, 70)
No titration 28 8.3 56
With ezetimibe 36 9.8 86
Reduced compliance 24 — 46
Pravastatin 20–40 mg
Base-case (95% CI) 30 (28, 33) 4.4 (2.1, 6.6) 60 (50, 70)
No titration 28 8.3 56
With ezetimibe 36 9.8 86
Reduced compliance 24 — 46
Rosuvastatin 10–40 mg
Base-case (95% CI) 46 (44, 48) 7.3 (5.4, 9.1) 87 (83, 92)
No titration 49 11.3 89
With ezetimibe 50 11.7 99
Reduced compliance 36 — 67
Simvastatin 20–80 mg
Base-case (95% CI) 37 (34, 39) 6.1 (3.5, 8.7) 73 (64, 81)
No titration 37 9.2 72
With ezetimibe 42 10.1 91
Reduced compliance 29 — 53
Upper and lower bounds of the 95% CI were used in one-way sensitivity analyses.
ATP II, National Cholesterol Education Program, Second Adult Treatment Panel; CI, conﬁdence interval; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-
density lipoprotein cholesterol; —, not available.
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Compliance with statin therapy was assumed to
be 100% in the base-case analysis, because this
study pertained only to patients who completed
52 weeks of follow-up, and because differences in
adherence between the statins have not been docu-
mented. In a separate scenario, the sensitivity of
base-case results to reduced compliance was tested.
Adverse Events and Long-Term Outcomes
Adverse events were not calculated in the model
because available evidence suggests that treatment-
limiting event rates do not differ signiﬁcantly
between the statins [21,22,33]. Moreover, the aver-
age cost of adverse events would be low, because
most events resolve after discontinuation of the
drug [2–8]. Although long-term postmarketing
safety data are not yet available for rosuvastatin,
cases of rhabdomyolysis are very rare and similar in
frequency to the other marketed statins [34].
Also excluded were costs for future clinical out-
comes such as myocardial infarction, stroke, coro-
nary artery bypass grafting or percutaneous
transluminal coronary angioplasty, even though sta-
tin therapy has been shown to reduce the frequency
of these procedures [2–8]. Excluding these potential
cost offsets is consistent with the short-term time
frame of the analysis and gives a more conservative
estimate of the cost-effectiveness of statin therapy,
particularly among the most effective statins [35].
Sensitivity Analyses and Alternate Scenarios
To determine the robustness of base-case ﬁndings,
alternate assumptions about each variable in the
model were tested. In addition to one-way sensitiv-
ity analyses on each variable, a Monte Carlo simu-
lation was used to vary all effectiveness inputs at
once [36,37]. The best-ﬁtting continuous probabil-
ity distribution for each drug’s effectiveness was
mathematically identiﬁed from the patient-level
clinical trial data. Lovastatin and ﬂuvastatin were
assigned their own distributions (with the same
parameters as pravastatin, as explained earlier), to
allow their effectiveness to vary independently from
pravastatin in the simulation. Although costs varied
with the number of titrations required to reach the
goal, statin prices were not varied in the Monte
Carlo simulation, as they are constant within a
health plan. Values from each probability distribu-
tion were randomly selected as the model generated
1000 populations of 10,000 patients each. Cost-
effectiveness acceptability curves were plotted to
display the optimal alternatives as a function of
willingness-to-pay for incremental effectiveness
[37].
In addition, the impacts of ﬁve alternate scenar-
ios that may be reﬂective of actual practice were
also studied. The ﬁrst scenario assumed that
patients were not titrated to goal, but instead com-
pleted the year on the initial statin dose. For this
analysis, effectiveness at the initial dose was carried
forward from the 12-week visit in the clinical trials.
In a second scenario, it was assumed that ezetimibe
10 mg was added to statin therapy in lieu of titra-
tion for patients who did not achieve LDL-C goal.
Patients were assumed to incur an additional visit
and lipid panel when initiating ezetimibe, as well as
Table 2 Cost parameters (in 2004 US dollars)
Parameter Base-case Low value High value
Physician visit (CPT 99214) 82.62 21.60 120.14
Lipid panel (CPT 80061) 18.19 13.69 18.75
Liver function test (CPT 80076) 11.02 6.41 11.42
Creatine kinase (CPT 82550) 9.08 8.62 9.10
Lipid-lowering drugs (per day)
Atorvastatin
10 mg 2.17 1.63 2.71
20/40/80 mg 3.15 2.36 3.94
Ezetimibe
10 mg 2.28 1.71 2.85
Fluvastatin
40 mg 1.75 1.31 2.19
80 mg 2.25 1.69 2.81
Lovastatin
20 mg 1.34 1.01 1.68
40 mg 2.44 1.83 3.05
Pravastatin
20 mg 2.79 2.09 3.49
40 mg 4.10 3.08 5.13
Rosuvastatin
10/20/40 mg 2.36 1.77 2.95
Simvastatin
20/40/80 mg 3.97 2.98 4.96
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the cost of the drug. The additional effectiveness
with ezetimibe add-on therapy was estimated based
on efﬁcacy data for patients who have ezetimibe
added to an ongoing HMG-CoA therapy regimen
which is contained on the product label [38]. The
third scenario explored the potential impact of non-
compliance on cost-effectiveness. Statin, physician,
and laboratory utilization were reduced by 16%
based on data from a 12-month study of statin com-
pliance among managed care enrollees [39]. Effec-
tiveness in terms of LDL-C reduction was adjusted
downward by 20% in this scenario [40]. Although
the Olsson [21] and Brown [22] trials were not
powered to detect differences in effectiveness across
NCEP ATP II risk subgroups, scenario four
examined cost-effectiveness by NCEP ATP II risk
group. Finally, the ﬁfth scenario examined cost-
effectiveness over a 3-year time horizon, consistent
with the recommendations of the AMCP Format for
Formulary submissions [18].
Results
Base-Case Analysis
In the base-case analysis, the mean reductions in
LDL-C for rosuvastatin, atorvastatin, and sim-
vastatin were 46%, 38%, and 37%, respectively.
Pravastatin, lovastatin, and ﬂuvastatin had mean
LDL-C reductions of 30%. Generic lovastatin had
the lowest ﬁrst-year cost of therapy ($1208), fol-
lowed by ﬂuvastatin ($1242), rosuvastatin ($1326),
atorvastatin ($1401), pravastatin ($1778), and
simvastatin ($1955). When the drugs were com-
pared for incremental cost-effectiveness, lovastatin
dominated ﬂuvastatin, whereas rosuvastatin domi-
nated atorvastatin, simvastatin, and pravastatin
(Tables 3, 4, and 5). The ﬁrst-year incremental cost
of rosuvastatin was thus $118 compared with lov-
astatin, or $8 per additional 1% reduction in LDL-
C, $436 per additional patient to ATP II goal, and
$41 per additional 1% increase in HDL-C.
Atorvastatin 10 mg had a lower acquisition cost
than rosuvastatin 10 mg, yet the total ﬁrst-year cost
of rosuvastatin was lower because of greater
effectiveness at the starting dose, which prevented
titrations in all but 16% of patients. Moreover, the
ﬂat price of rosuvastatin minimized the economic
impact when patients were titrated. Conversely,
37% of patients treated with atorvastatin required
at least one titration. In addition to more frequent
physician monitoring and laboratory tests, drug
costs increased substantially at higher doses of ator-
vastatin.
Sensitivity Analyses
Base-case results were most sensitive to the acquisi-
tion costs of rosuvastatin, atorvastatin, and lovas-
tatin. A decrease in the price of rosuvastatin by 14%
Table 3 1-year and 3-year base-case cost per 1% reduction in LDL-C
Strategy
Average cost ($) Incremental cost ($) Average %
↓ LDL-C
Incremental % ↓ LDL-C
Incremental cost- 
effectiveness ratio 
($/1% ↓ LDL-C)
1-year 3-year 1-year 3-year 1-year 3-year 1-year 3-year
Lovastatin 1280 3120 — — 30 — — — —
Fluvastatin 1242 3177 Dominated Dominated 30 Dominated Dominated Dominated Dominated
Rosuvastatin 1326 3476 118 356 46 16 16 8 23
Atorvastatin 1401 3676 Dominated Dominated 38 Dominated Dominated Dominated Dominated
Pravastatin 1778 4846 Dominated Dominated 30 Dominated Dominated Dominated Dominated
Simvastatin 1955 5280 Dominated Dominated 37 Dominated Dominated Dominated Dominated
Cost-effectiveness ratios were calculated before cost and effectiveness estimates were rounded.
LDL-C, low-density lipoprotein cholesterol; —, not applicable.
Table 4 1-year and 3-year base-case cost per patient to ATP II goal*
Strategy
Average cost ($) Incremental cost ($) Average patients
to ATP II goal
Incremental patients to 
ATP II goal
Incremental cost- 
effectiveness ratio 
($/patient to ATP II goal)
1-year 3-year 1-year 3-year 1-year 3-year 1-year 3-year
Lovastatin 12,080,450 31,197,003 — — 6,000 — — — —
Fluvastatin 12,424,554 31,767,946 Dominated Dominated 6,000 Dominated Dominated Dominated Dominated
Rosuvastatin 13,264,305 34,756,905 1,183,855 3,559,902 8,713 2,713 2,713 436 1,312
Atorvastatin 14,005,258 36,763,638 Dominated Dominated 8,017 Dominated Dominated Dominated Dominated
Pravastatin 17,780,272 48,457,949 Dominated Dominated 6,000 Dominated Dominated Dominated Dominated
Simvastatin 19,547,992 52,801,642 Dominated Dominated 7,255 Dominated Dominated Dominated Dominated
*Assuming 10,000 patients treated with each statin.
Cost-effectiveness ratios were calculated before cost and effectiveness estimates were rounded.
ATP II, National Cholesterol Education Program, Second Adult Treatment Panel; —, not applicable.
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or more made it the least costly and most effective
alternative, dominating all other statins. Conversely,
for prices up to 30% greater than its WAC, rosuv-
astatin remained the only branded statin on the efﬁ-
cient frontier. Nevertheless, the ICER at WAC plus
30% was $24 per additional 1% decrease in LDL
(three times the base case ICER), compared with
lovastatin. When the price of atorvastatin was dis-
counted 15% below WAC, it joined the efﬁcient
frontier with an ICER of $7 per additional 1%
decrease in LDL compared with lovastatin. The
ICER for rosuvastatin in that scenario was $8 com-
pared with atorvastatin. When atorvastatin was dis-
counted 24% or more, it became the least costly
statin, and the ICER for rosuvastatin was $18 per
additional 1% decrease in LDL. When the average
price of lovastatin was replaced with the lowest
available price (36% less than the base-case price),
its total cost in year 1 was $956, and the ICER for
rosuvastatin was $24 per additional 1% decrease in
LDL compared with lovastatin. Pravastatin and sim-
vastatin remained dominated until their base-case
prices were discounted 45% and 49%, respectively.
Results were moderately sensitive to assumptions
about HDL-C improvement. Moderate increases in
the base-case HDL-C beneﬁts of simvastatin and
ﬂuvastatin were sufﬁcient for these products to
avoid being dominated. For example, if ﬂuvastatin
improved HDL-C by 6.6%, it joined the efﬁcient
frontier, and the ICER for rosuvastatin increased
threefold ($123 per additional 1% increase in HDL-
C compared with ﬂuvastatin). When simvastatin
was assumed to increase HDL-C by 8.7%, it joined
the efﬁcient frontier, but its relatively high price
yielded an ICER of $443 per additional 1% im-
provement in HDL-C, compared with rosuvastatin.
Results were insensitive to the cost of physician
visits and lab procedures, as well as to variations in
effectiveness over the 95% conﬁdence limits for
LDL-C reduction. At its upper conﬁdence limit for
ATP II goal achievement, atorvastatin was the most
effective statin. Nevertheless, its higher price and
small incremental beneﬁt relative to rosuvastatin
yielded a high ICER ($27,313 per additional patient
to goal versus rosuvastatin). Results did not differ
substantially from the base case when costs and
beneﬁts were imputed for patients who discontin-
ued therapy during the study year.
Figure 2 provides the cost-effectiveness accepta-
bility frontier for each outcome of interest, based on
1000 simulated populations of 10,000 patients
each. In all cases, the frontier included only lovas-
tatin and rosuvastatin. The intersection of the lines
illustrates the willingness-to-pay threshold where
the optimal drug of choice changes from lovastatin
to rosuvastatin. These willingness-to-pay thresholds
are approximately $8, $434, and $40 for a 1%
reduction in LDL-C, one additional patient to ATP
II goal, and a 1% increase in HDL-C, respectively.
Alternative Scenarios
When patients were assumed to remain at their
respective starting doses and 12-week effectiveness
persisted for the full year, lovastatin remained the
least costly alternative ($933), followed by ﬂuvas-
tatin ($1083), atorvastatin ($1236), rosuvastatin
($1305), pravastatin ($1463), and simvastatin
($1894). Although atorvastatin was less costly than
rosuvastatin in this scenario, atorvastatin was still
dominated in the extended sense because rosuvas-
tatin had a lower incremental cost per additional
unit of beneﬁt compared with lovastatin.
When patients received add-on therapy with
ezetimibe instead of statin titration, lovastatin
remained the least costly strategy and rosuvastatin
was the most effective, with an ICER of $10 per
additional 1% reduction in LDL-C. Rosuvastatin
dominated ﬂuvastatin, atorvastatin, pravastatin,
and simvastatin. Similarly, when resource use and
effectiveness were adjusted for compliance rates
representative of actual practice, the results were
virtually identical to the base-case.
Table 5 1-year and 3-year base-case cost per 1% increase in HDL-C
Strategy
Average cost ($) Incremental cost ($) Average 
% ↑ HDL-C
Incremental % ↑ HDL-C
Incremental cost-
effectiveness ratio 
($/1% ↑ HDL-C) 
1-year 3-year 1-year 3-year 1-year 3-year 1-year 3-year
Lovastatin 1208 3120 — — 4.4 — — — —
Fluvastatin 1242 3177 Dominated Dominated 4.4 Dominated Dominated Dominated Dominated
Rosuvastatin 1326 3476 118 356 7.3 2.9 2.9 41 122
Atorvastatin 1401 3676 Dominated Dominated 0.9 Dominated Dominated Dominated Dominated
Pravastatin 1778 4846 Dominated Dominated 4.4 Dominated Dominated Dominated Dominated
Simvastatin 1955 5280 Dominated Dominated 6.1 Dominated Dominated Dominated Dominated
Cost-effectiveness ratios were calculated before cost and effectiveness estimates were rounded.
HDL-C, high-density lipoprotein cholesterol; —, not applicable.
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In the subanalysis of cost-effectiveness by NCEP
ATP II risk group, the base-case results remained rel-
atively stable, but the cost-effectiveness ratio for
rosuvastatin was most favorable for patients at high
risk of coronary events. The incremental cost per ad-
ditional 1% reduction in LDL for rosuvastatin ver-
sus lovastatin was $6, $10, and $7 in the high-risk,
moderately high risk, and low-risk groups, respec-
tively. These ratios reﬂect the fact that LDL reduc-
tions were greatest among the high-risk patients
(51% for rosuvastatin and 32% for lovastatin), fol-
lowed by low-risk patients (46% and 29%), and
moderately high risk patients (43% and 31%).
Finally, when the base-case scenario was
evaluated using a 3-year time horizon, total costs
increased to reﬂect longer-term statin use (Tables 3,
4, and 5). Nevertheless, effectiveness was the same
as in the 1-year analysis because, under recom-
mended monitoring and titration intervals, all titra-
tions occur within the ﬁrst year of treatment. Thus,
the ICERs in the 3-year analysis may be interpreted
as the cost to maintain a given level of effectiveness
for 3 years.
Discussion
This CEA compared currently available statins in
patients with dyslipidemia from the perspective of a
managed care payer. When patients were titrated to
ATP II goals, the most effective strategy was rosu-
vastatin over the 10 mg to 40 mg dose range. Ator-
vastatin, simvastatin, and pravastatin were less
effective and more costly than rosuvastatin. Lovas-
tatin over the 20 mg to 40 mg range was the least
costly strategy, followed by ﬂuvastatin over the
40 mg to 80 mg range. Compared with lovastatin,
the incremental cost of rosuvastatin was $118 per
patient in the initial year of therapy, or $8 per addi-
tional 1% reduction in LDL-C, $41 per additional
1% increase in HDL-C, and $436 per additional
patient to ATP II goal. These ratios increased by as
much as three times as the price of generic lovasta-
tin was reduced from the average of all available
manufacturers to the lowest published price.
These ﬁndings have potentially important impli-
cations for managed care decision-makers. Under
the base-case and each alternative scenario, atorv-
astatin, pravastatin, and simvastatin were always
dominated. Thus, depending on actual acquisition
prices, payers may achieve substantial cost savings
and greater effectiveness by using rosuvastatin
instead of these agents. In the Monte Carlo simula-
tion of 1000 populations, the cost-effectiveness
acceptability curves favored generic lovastatin and
rosuvastatin as the optimal formulary. This conclu-
sion was consistent with that of Morrison and
Glassberg, who asserted that a cost-effective
approach to lipid-lowering therapy would be to
treat low-risk patients and those with lower base-
Figure 2 Results of Monte Carlo simulation. (A) Cost-effectiveness
acceptability curves for LDL-C reduction. The threshold is inter-
preted as the point at which each therapy is optimal 50% of the time
based on an expressed willingness to pay for each incremental 1%
reduction in LDL-C. (B) Cost-effectiveness acceptability curves for
HDL-C increase. The threshold is interpreted as the point at which
each therapy is optimal 50% of the time based on an expressed will-
ingness to pay for each incremental 1% increase in HDL-C. (C) Cost-
effectiveness acceptability curves for ATP II goal achievement. The
threshold is interpreted as the point at which each therapy is optimal
50% of the time based on an expressed willingness to pay for each
incremental patient to ATP II goal.
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line LDL-C levels with the least costly statin, while
using the most effective drug in high-risk patients
and those with high baseline LDL-C levels [41]. The
present study extends those theoretical ﬁndings
based on currently available pricing and clinical
data. Moreover, the results of this analysis can be
used to calculate the trade-offs inherent in selecting
a different formulary. For example, a payer might
consider placing generic lovastatin and simvastatin
on formulary until long-term outcomes and safety
data become available for rosuvastatin. Assuming
10,000 patients treated with each product, in year 1
the choice of simvastatin would cost about $6.3
million more than rosuvastatin, and 1458 fewer
patients would achieve ATP II LDL-C goals.
There remains an important question of whether
the additional cost of rosuvastatin compared with
lovastatin ($436 per additional patient to LDL-C
goal) constitutes good value for money [42]. To put
this in a decision-making context, the analysis may
be recalculated in the absence of rosuvastatin. The
next most effective alternative is atorvastatin, which
is currently on many formularies. Under base-case
assumptions, atorvastatin, in the absence of rosuv-
astatin, has an incremental cost per patient to goal
of $954, compared with lovastatin. Thus, rosuvas-
tatin is able to get more patients to goal than ator-
vastatin, and at a 54% lower incremental cost per
patient to goal.
This analysis was unique in its analytic
approach, because it was neither purely trial-based
nor purely model-based. Typical trial-based analy-
ses are subject to the limitations of protocol-driven
resource use, which does not apply to real-world
populations. Conversely, purely model-based anal-
yses require that multiple sources of data be synthe-
sized and extrapolated to common endpoints in
ways that enhance external validity at the expense
of internal validity. Given that no long-term out-
comes or safety studies are yet available for rosuv-
astatin or ezetimibe, we developed a simple model
based on clinical guidelines for the management of
dyslipidemia patients, but limited the base-case time
horizon and effectiveness endpoints to those used in
the available clinical trials. This approach thus
placed the available clinical data in the context of a
real-world formulary decision, thereby balancing
the tradeoffs between internal and external validity.
It may well be a useful method for evaluating new
products in other therapeutic areas.
These ﬁndings should be interpreted in light of
some limitations. Because the objective was to iden-
tify the optimal combination of statins for a man-
aged care formulary, several nonstatin medications
for dyslipidemia (e.g., niacin, ﬁbrates, and bile
sequestrants) were excluded from analysis. These
products generally have a secondary role in therapy,
are relatively inexpensive, and were not expected to
inﬂuence the relative cost-effectiveness of products
in the statin class. Their exclusion from this analysis
should not be construed to mean that they are not
cost-effective agents for modifying serum lipids.
The effectiveness of atorvastatin, pravastatin, rosu-
vastatin, and simvastatin were estimated based on
data from two Phase III trials. Fluvastatin and lov-
astatin were assumed to be equivalent to pravasta-
tin over the dose ranges speciﬁed, because long-term
trials have not compared ﬂuvastatin and lovastatin
with rosuvastatin. Although the resulting estimates
for each drug are consistent with numerous other
trials and product labels, and although these esti-
mates were varied in sensitivity analyses, the results
may not apply to patient populations with different
characteristics than those in the Olsson [21] and
Brown [22] trials. The subgroup analysis by NCEP
ATP II risk group should be interpreted with cau-
tion, as the trials were not powered to detect differ-
ences in effectiveness across risk strata. Costs were
estimated using published WAC for drugs and
Medicare reimbursement rates for physician visits
and laboratory procedures. These costs may not
reﬂect the actual costs negotiated by managed care
organizations, but wide variation in these parame-
ters were probed to ﬁnd relevant thresholds that
changed the optimal formulary. Costs associated
with adverse drug events and nonstudy medications
were excluded, but these were not expected to differ
across treatment groups, and therefore would not
have affected the incremental analysis.
This analysis had a 1- to 3-year time horizon, and
therefore examined surrogate endpoints instead of
long-term outcomes such as cost per life-year
gained. Although long-term head-to-head outcomes
studies comparing the agents in this analysis would
be a preferable data source [43], decisions must be
made based on currently available data. As such,
this model informs payers of the trade-offs inherent
in covering one statin (or combination of statins)
over another. Moreover, studying surrogate end-
points in this analysis yielded conservative estimates
of the incremental effectiveness of rosuvastatin.
Estimating long-term events prevented and associ-
ated cost offsets based on recent clinical trial data
[35] would increase the incremental effectiveness
and decrease the incremental cost of rosuvastatin.
Finally, achievement of ATP III LDL-C goals could
not be measured because patients were titrated to
ATP II goals in the Olsson [23] and Brown [24] tri-
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als. Nevertheless, a recent head-to-head trial of ATP
III goal achievement after 6 weeks of treatment with
rosuvastatin, atorvastatin, simvastatin, or pravasta-
tin resulted in incrementally higher goal achieve-
ment with rosuvastatin [44]. The magnitude of the
incremental effectiveness was similar to the inputs
employed in the present analysis.
In conclusion, the ﬁndings of this analysis indi-
cate that rosuvastatin is less costly and more effec-
tive than atorvastatin, pravastatin, and simvastatin
over the dose ranges for which comparative data are
available. Compared with ﬂuvastatin and pravasta-
tin, generic lovastatin is cost-saving and about as
effective. Therefore, generic lovastatin and rosuvas-
tatin comprise the optimal two-statin formulary.
Compared with generic lovastatin, rosuvastatin
offers substantial additional LDL-C reduction,
HDL-C improvement, and NCEP goal achievement
at a reasonable additional cost, depending on the
payer’s willingness to pay for these beneﬁts. Formu-
lary decisions based on these results should be revis-
ited periodically, as new pricing, outcomes and
safety data become available.
Source of ﬁnancial support: This research was sponsored
by AstraZeneca.
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